Close Menu
News Article

Trevett announces resignation as Texas Biomed CEO

Trevett Announces Resignation as Texas Biomed CEO
Will Continue Until Successor is Hired

SAN ANTONIO, May 28, 2014 – Texas Biomedical Research Institute has announced the resignation of Kenneth P. Trevett as its President and CEO, according to Board Chairman Richard Schlosberg.  Trevett will continue in the position until a successor is hired.

Trevett joined Texas Biomed as president in September, 2008, coming from the Los Angeles Biomedical Research Institute, where he had served as President and CEO from 2001-2008.  His career working with biomedical research, educational and service institutions has spanned more than 35 years and has included leadership positions at Schepens Eye Research Institute in Boston, Dana-Farber Cancer Institute, The Jackson Laboratory and Tufts University School of Veterinary Medicine.

“Ken came to us at a critical time,” Schlosberg said.  “He led us through the re-naming and re-branding of the institution from Southwest Foundation for Biomedical Research to Texas Biomedical Research Institute, completed a comprehensive planning process which identified key needs and opportunities, and helped spearhead a successful $32 million fundraising effort.  That capital campaign enabled the construction of the 70,000 square-foot Earl Slick Research Center, a new laboratory and scientific support building which just opened in late March, as well as a major effort now underway to recruit new, world-class scientists.  In fact, Ken was recently recognized as a ‘Health Care Hero for Philanthropy’ by the San Antonio Business Journal for his accomplishments.”

“Announcing my resignation is a bittersweet moment for me,” Trevett said.  “I feel very good about what we’ve been able to accomplish in just six years, both here at Texas Biomed and in helping build San Antonio’s life science infrastructure.  I am honored to serve as Chairman of BioMed SA, which works to accelerate growth and build the international reputation of the city’s healthcare and bioscience sector.  We’ve been able to create the San Antonio Vaccine Development Center, which includes Texas Biomed, Southwest Research Institute, the University of Texas at San Antonio and the University of Texas Health Science Center-San Antonio, to promote excellence in vaccine research and development.”

“But, this is also a good time for me to make my own transition from this role and let a successor take it from here,” he said.  “After more than three decades working with these kinds of institutions, I want to look at other opportunities where my background in management and business operations can be applied.  That’s a new chapter for me and it opens up all sorts of horizons, so I’m excited about the possibilities. I do want to continue to serve on the various not-for-profit boards in the city where I think I can continue to have an impact.”

Trevett also serves on the Executive Committee of the United Way, and the boards of the San Antonio Medical Foundation and the Texas Research & Technology Foundation.  He is a member of the Advisory Board of the Southwest Research Institute.

“We appreciate Ken’s flexibility in giving us time to bring in an individual with recognized, proven leadership skills, outstanding scientific credentials, and vision to establish the next phase of biomedical research excellence for the years to come,” Schlosberg said.  “Texas Biomed is one of the leading biomedical research institutions in the nation and is recognized internationally for the quality of science our researchers perform.  The Board will move right away to hire a distinguished individual who will take the institute from its present strong foundation to the next level of excellence and further expansion of its domestic and international reputation.”

Texas Biomed, formerly the Southwest Foundation for Biomedical Research, is one of the world’s leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research.  Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers, and parasitic diseases responsible for malaria, schistosomiasis and Chagas disease. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases.  For more information on Texas Biomed, go to